244 results about "Nasopharyngeal cancer" patented technology

The invention discloses a nasopharyngeal carcinoma radiotherapy target region automatic segmentation method based on a deep neural network, and belongs to the field of nasopharyngeal carcinoma radiotherapy target region automatic segmentation. The method comprises the following steps: acquiring CT image data of a patient, sketching a nasopharyngeal carcinoma radiotherapy target region and endangering organs based on the CT image data, and dividing the sketched CT image data into a training set and a verification set; constructing a deep neural network segmentation model, preprocessing trainingsamples in the training set, using the preprocessed training samples for training the deep neural network segmentation model, wherein preprocessing comprises the steps of reducing the numerical rangeof the training samples to a specified range and augmenting the training samples; and reducing the numerical range of the training samples in the verification set to a specified range, inputting thenumerical range into the trained deep neural network segmentation model, and quantitatively evaluating the recognition effect of the model. According to the invention, the model can automatically output the segmentation result of the nasopharyngeal carcinoma radiotherapy target area and organs endangering the nasopharyngeal carcinoma radiotherapy target area in a short time only by inputting the CT image data of the patient.

The invention relates to an auxiliary assessment method for prognosis of nasopharynx cancer based on enhanced MRI radiomics. The auxiliary assessment method comprises the steps of: (1), performing MRIimage processing; (2), extracting imaging features; (3), screening the imaging features; (4), establishing a radiomics scoring formula; (5), screening clinical risk factors; and (6), establishing a prognostic survival model: establishing a prognostic observation model through combination of a radiomics score and the clinical risk factors of a patient with nasopharynx cancer, performing qualitative and quantitative prediction on the PFS (progression free survival) of the patient, and furthermore, assessing the performance of the prognostic survival model. The auxiliary assessment method in theinvention has little harm to the image examination of the patient; qualitative and quantitative analysis on the survival time of a specific patient is carried out; therefore, a doctor is assisted tomake an individualized treatment and follow-up visit scheme; furthermore, the doctor is assisted to assess the survival and recurrence time of the patient; simultaneously, the performance of the obtained prognostic survival model is verified; and thus, the accuracy of a prognostic prediction model is ensured.

The invention pertains to the field of traditional Chinese medicine for treating tumors and provides a traditional Chinese medicine for treating nasopharyngeal cancer, which is characterized by good curative effect and high efficiency. The traditional Chinese medicine for treating nasopharyngeal cancer is prepared from traditional Chinese medicinal materials including faeces trogopterorum, lacca sinica exsiccate, panax pseudoginseng, selaginella doederleinii hieron, glossy ganoderma, radix sophorae tonkinensis, angelica, rhizoma bolbostemmae, scolopendra and the like, can strengthen the body resistance and consolidate the constitution, benefit Qi and nourish the blood, promote blood circulation to remove blood stasis, clear away heat and toxic materials and fight against cancer, and has the advantages of good curative effect, high efficiency and remarkable result.

The invention discloses a nasopharyngeal carcinoma auxiliary diagnosis model construction and auxiliary diagnosis method and system, and relates to the technical field of medical data processing. Thenasopharyngeal carcinoma auxiliary diagnosis model construction method comprises the steps: sample acquiring: acquiring a nasal endoscope image, wherein the nasal endoscope image comprises a nasopharyngeal carcinoma group and a non-nasopharyngeal carcinoma group; preprocessing: preprocessing the nasal endoscope image; and model training: inputting the preprocessed nasal endoscope image into a convolutional neural network, and training the convolutional neural network to obtain a nasopharyngeal carcinoma auxiliary diagnosis model. According to the invention, the nasopharyngeal endoscope image can be analyzed, and the predicted illness probability is output in real time to assist a doctor in nasopharyngeal carcinoma diagnosis, so that the accuracy of nasopharyngeal carcinoma diagnosis can beeffectively improved, and the biopsy detection rate is increased so as to achieve the purposes of early screening, early diagnosis and early treatment of nasopharyngeal carcinoma and improvement of treatment effect and prognosis of patients.

The invention discloses tetrahydropalmatine derivatives and a preparation method and application thereof. The structural formula of the tetrahydropalmatine derivatives is shown as a formula II, wherein R is octyl, isopropyl or 3-methybutyl. The provided application is the application of the tetrahydropalmatine derivatives shown as the formula II or pharmaceutically acceptable salts thereof in the preparation of eukaryotic tumor cell antiblastics and medicaments for preventing and/or treating tumors. The results of in-vitro anti-tumor activity experiments prove that each tetrahydropalmatine derivative has the effect of inhibiting human lung cancer cells A-549, KB human nasopharyngeal carcinoma cells, and HL-60 leukemia cell strains to a certain extent. The results show that the tetrahydropalmatine derivatives shown as the formula II can be applied to preparing the medicaments for treating the tumors, and the pharmaceutical application of the tetrahydropalmatine derivatives is widened.

The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2/M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.

The invention discloses a tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis. The tumor microenvironment component marker combination comprises a cell cycle proliferation component and at least one of five immune cell components including macrophages, plasmacytoid dendritic cells, CLEC9A + dendritic cells, natural killer cells and plasma cells. According to some examples of the invention, the expression levels of different components in a nasopharyngeal carcinoma tumor microenvironment can be predicted by calculating the expressionlevels of respective feature genes of one tumor cell component and five immunocyte components, and clinical prognosis prediction can be performed on a nasopharyngeal carcinoma patient, so that individualized treatment is facilitated, and finally, survival benefits are brought to the patient.

The invention provides a method for preparing gynecological menstruation regulating tablets. The menstruation regulating tablets are prepared from 144g of Chinese angelica, 16g of Szechuan lovage rhizome, 400g of vinegar baked rhizoma cyperi, 23g of bran baked bighead atractylodes rhizome, 12g of white peony root, 12g of red peony root, 32g of vinegar baked corydalis tuber, 48g of prepared rehmannia root, 80g of jujube and 11g of licorice serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the ferulic acid content is greatly improved. The invention also provides application of the gynecological menstruation regulating tablets in preparation of a medicament for inhibiting propagation of human nasopharyngeal carcinoma CNE-2Z cells.

The invention provides a method for establishing a human nasopharyngeal carcinoma tumor stem cell line. The method comprises the following steps: (1) obtaining human nasopharyngeal carcinoma cells in the single cell state; (2) adding the human nasopharyngeal carcinoma cells in the single cell state, obtained in the step (1), to a serum-free stem cell culture medium containing epidermal growth factors and basic fibroblast growth factors to obtain single cell suspension; (3) adjusting the concentration of the single cell suspension in the step (2) to 900-1100 single cells/ml; (4) inoculating 1ml of the single cell suspension obtained in the step (3) into single pores on a cell culture six-pore plate and then adding the equivoluminal stem cell culture medium for culture for 72-96 hours; and (5) collecting the cells obtained in the step (4), carrying out trypsinization till the single cell and carrying out subculture. The method provided by the invention is simple and convenient to operate; and the obtained nasopharyngeal carcinoma stem cell line has obvious stem cell characteristics.

The invention discloses a method for screening nasopharyngeal carcinoma radiotherapy resistant cells by using a radioactive irradiation mode. The method adopts a screening mode of radioactive gradient increasing. By adopting the method, cells can adapt to high-dose radioactive irradiation more rapidly within a relatively short time, the time of growth recovery after single high-dose radioactive irradiation can be shortened, the possibility of generating radiotherapy resistance can be increased, and meanwhile, the investment of manpower, material resources and time can be reduced. The constructed nasopharyngeal carcinoma radiotherapy resistant cells are used for providing a good cell model for the study on nasopharyngeal carcinoma radiotherapy resistance. The method disclosed by the invention is suitable for nasopharyngeal carcinoma cell strains cultured in vitro, and also can be used for providing references for the establishment of other tumor radiotherapy resistant cells.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention discloses an NPC (nasopharyngeal carcinoma) related tumor marker and an application. The tumor marker is lncRNA, is positioned at the 17th chromosome chr17:47785696-47797422 and has the nucleotide sequence shown in SEQ ID NO.1 and named as lncRNA-KAT7. According to the sequence lncRNA-KAT7, the specific real-time fluorescent quantitative PCR primer is designed and synthesized, and a preparation used for NPC diagnosis or curative effect prediction is prepared. Detection of the expression level of lncRNA-KAT7 in an NPC clinical case specimen by use of the real-time fluorescent quantitative PCR preparation proves that expression of lncRNA-KAT7 in NPC is remarkably reduced, and lncRNA-KAT7 can be used for preparing a preparation or a kit for auxiliary diagnosis, curative effect prediction and prognosis of NPC.

The invention discloses a molecular target hsa-miR203 for diagnosing and treating nasopharyngeal cancer related with Epstein-Barr virus (EBV) infection and application thereof. The microRNA can accurately reflect the conditions of retention and loss of EBV viruses in cells and tissues, and further can be used for diagnosing the nasopharyngeal cancer related with the EBV infection; and meanwhile, target genes E2F3, CCNG1 and the like controlled by the hsa-miR203 obviously inhibit the proliferation and conversion capacities of the cells, so the hsa-miR203 can be used for treating the nasopharyngeal cancer related with the EBV infection. Therefore, the hsa-miR203 has important scientific research theory and clinical application value, and provides new clue and proof for diagnosis, treatment or prognosis of EBV related tumors.

The invention discloses the application of human lactoferrin (hLTF) and its ELISA detection kit in diagnosis of nasopharyngeal carcinoma. The invention proves the specific down-regulation of hLTF gene in nasopharyngeal carcinoma tissue by experiments so as to provide the use of hLTF in diagnosis, screening and prognosis of nasopharyngeal carcinoma. The invention further provides an anti-hLTF antibody and an hLTF ELISA detection kit for diagnosis of nasopharyngeal carcinoma by double-antibody sandwich method. The expression level of LTF in nasopharyngeal secretion from different people can be quantitatively detected by collecting secretion from nasopharynx with ELISA method, so as to predict the risk of nasopharyngeal carcinoma, screen susceptible persons, and perform early and rapid non-invasive diagnosis to nasopharyngeal carcinoma patients.

The invention relates to a traditional Chinese medicine composition for treating cancers, which contains three active components, including chan garment, acanthopanax and tolypocladium sinensis mycelia, wherein the cancers include solid tumor, preferably liver cancer, lung cancer, breast cancer, esophagus cancer, stomach cancer, nasopharyngeal cancer, ovarian cancer, bladder cancer, rectal cancer,skin cancer and lymphoma, and further preferably liver cancer; particularly, the traditional Chinese medicine composition has specially and obviously effect of treating liver cancer with cirrhosis and ascites. The chan garment, acanthopanax and tolypocladium sinensis mycelia preparation not only has amazing treating effect on tumors as diseases upsetting human beings, but also utilizes the chan garment generated by the naturally molting phenomenon of a bufonid, thereby not only effectively utilizing resources, but also protecting the ecological environment.

The invention relates to an application of a CXCR2 inhibitor in preparation of a medicine for treating nasopharynx cancer, and belongs to the field of medicine. The invention provides an application of a CXCR2 inhibitor in preparation of a medicine for treating nasopharynx cancer or preventing nasopharynx cancer relapse, an application in preparation of a radiotherapy sensitizer for nasopharynx cancer and an application in preparation of a radiotherapy protective agent for nasopharynx cancer. The application of the invention is helpful for reducing toxic and side effects caused by clinical radiation therapy of nasopharyngeal carcinoma, improving the life quality of nasopharyngeal carcinoma patients and the curative effect of advanced nasopharyngeal carcinoma patients, and providing a new thought and strategy for comprehensive treatment of nasopharyngeal carcinoma clinically.

The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.

The invention discloses a CBA kit used for detecting anti-EB virus gp78 antibody, which includes coupling superbead, the superbead is made by coupling blank superbead and NeutrAvidin in a coupling way, the NeutrAvidin binds with the bioepiderm labeled EB virus gp78 antigen which is coupled with Biotin. The gp78 antibody CBA kit is suitable for crown screening, evaluation of the high incidence of nasopharyngeal carcinoma, diagnose and prognosis effect appraisal, observation, furthermore, the kit can be applied directly in nasopharyngeal carcinoma early diagnosis, judge prognosis of patients, etc. with the characteristics of rapid, objectivity and accurate.

The invention provides application of zeylenone and derivatives thereof in preparation of anti-tumor drugs. The zeylenone is of a (+)-zeylenone configuration, and the molecular formula is shown as a formula (I). The derivative has a structure shown as a formula (II). The invention also provides a preparation method of zeylenone and the derivative thereof. The invention also provides application ofthe zeylenone and the derivative thereof or the zeylenone and the derivative thereof prepared by the preparation method of any one of the zeylenone and the derivative thereof in preparation of anti-tumor drugs. The tumor is selected from at least one of human brain glioma, human nasopharyngeal carcinoma, human liver cancer, human lung cancer, human neuroglioblastoma, human prostate cancer and mouse pancreatic cancer. The zeylenone and the derivative thereof are high in sensitivity and good in selectivity, and can be used for preparing anti-tumor drugs.

The invention discloses an SNP marker composition related to onset risk of brain radiation injury caused by tumor radiotherapy and application thereof. The SNP marker composition comprises 15 SNP loci. Meanwhile, a kit for predicating the onset risk of brain radiation injury caused by tumor radiotherapy is prepared, the kit is adopted to detect types of SNP markers, and the onset risk of onset risk of patients suffering from nasopharyngeal carcinoma can be more comprehensively and accurately detected estimated through clinic information of the patients. Through the adoption of the SNP marker composition to clinical applications, and adoption of protective measures in advance to high-risk patients, the SNP marker composition is beneficial to implementation of individualized treatment to thepatients, and improves the long-term survival quality of the patients suffering from nasopharyngeal carcinoma. Meanwhile, the SNP marker composition can provide a method and tactical reference for the predication of risk of normal tissue injury caused by other radiotherapies.